6 best EDC platforms for US clinical trials in 2026

When your study build takes longer than your sponsor's patience, the cost isn't just a delayed go-live -- it's a delayed first patient in, a compressed data review window, and a sponsor conversation you'd rather not have. Viedoc's EDC software goes live in as little as 8 weeks, with a no-code Designer your data management team can run independently, backed by 99.99% uptime across 7,500+ completed studies in 75+ countries. This comparison evaluates six leading electronic data capture (EDC) platforms for US clinical trials across build speed, FDA and HIPAA compliance credentials, no-code configuration, and total cost of ownership.

Running studies under FDA oversight means your platform choices carry regulatory weight that goes well beyond usability. 21 CFR Part 11 compliance, HIPAA attestation for handling protected health information (PHI), and a full electronic audit trail aren't differentiators in the US market -- they're table stakes. What actually separates platforms at shortlist is how quickly you can get studies live, how independently your team can manage amendments, and whether the vendor's cost model stays predictable as your study portfolio grows.

Enterprise platforms built for large pharma can take 90 days or more to configure a single study -- a timeline that's simply incompatible with the pace of Phase I/II trials and the economics of SMID CROs and growth-stage sponsors. The platforms reviewed here are evaluated on the criteria that matter most to US clinical operations teams: build velocity, self-service configurability, validated compliance documentation, FDA inspection readiness, and support quality across US time zones.

Best EDC solutions: quick comparison

These six EDC platforms represent the most evaluated options for US clinical trials, reviewed across build speed, compliance credentials, no-code configurability, and total cost of ownership.

1. Viedoc

For US clinical teams running Phase I/II studies or managing a concurrent study portfolio, build speed and FDA compliance documentation quality determine delivery margin as much as headcount does. Viedoc's EDC software goes live in as little as 8 weeks, powered by a no-code Designer that certified data managers operate independently -- no vendor-side programmer required for builds or amendments.

For US buyers, the two differentiators that move the most needles are speed and return on investment. The no-code Designer removes the vendor dependency that compounds amendment lag across a growing study portfolio, and Viedoc's unlimited user seat model means costs don't rise with headcount -- a critical advantage for SMID CROs and growth-stage sponsors managing tight study budgets. The Viedoc Inspection Readiness Packet (VIRP) provides structured, audit-ready documentation that supports computer system validation (CSV) workflows directly, reducing the time your QA team spends preparing for FDA inspections.

Viedoc is fully compliant with FDA 21 CFR Part 11, ICH GCP, GDPR, and EU Annex 11, with HIPAA attestation for US PHI handling. The platform is ISO 27001 and SOC 2 Type II certified, hosted on Microsoft Azure at 99.99% uptime, and available in 40+ languages across 75+ countries. Customer success is available 24/7 with direct escalation paths -- not a ticket-only model.

"My experience with Viedoc has been excellent. The database is very customizable and has been able to meet the needs of each of our studies. Customer Support has been excellent with quick turnarounds and response time." -- Amanda M., Sr. Clinical Program Manager

Verified proof points:

• Study scale: 7,500+ studies completed across 75+ countries
• User base: 140,000+ users globally; 30,000+ sites
• Build speed: Study builds in as little as 8 weeks; amendments completed in days
• Uptime: 99.99% platform uptime; hosted on Microsoft Azure
• Compliance: FDA 21 CFR Part 11, HIPAA attestation, ISO 27001, SOC 2 Type II certified
• Inspection readiness: VIRP available to all customers; supports FDA CSV workflows
• Pricing: Unlimited user seats; no per-user fees; transparent, study-based licensing
• No-code designer: In-house study configuration by certified data managers; no vendor programmer required

2. Medidata

Medidata offers Rave EDC, a cloud-based electronic data capture system that captures, manages, cleans, and reports clinical trial data across Phase I--IV studies. Rave EDC supports mid-study protocol amendments and changes without downtime and integrates with adjacent Medidata platform tools including eCOA, RTSM, and Clinical Data Studio for centralized monitoring. The platform includes AI-assisted study configuration tools designed to reduce setup time, and its Rave Lite offering provides a streamlined configuration path specifically for Phase I, Phase IV, and post-market studies. Medidata is the most widely installed EDC system across large pharma and global contract research organizations (CROs), with an extensive history of regulatory submissions to the FDA and other authorities.

3. Veeva Vault EDC

Veeva offers Vault EDC, a cloud-native electronic data capture application within its Vault Clinical Data Management (CDMS) suite. Vault EDC uses drag-and-drop study design that eliminates the need for custom programming, and supports protocol amendments without system downtime or data migration. The platform integrates natively with Vault CTMS and eTMF as part of the broader Vault Clinical Suite, providing a unified environment for sponsors managing clinical data alongside operational documentation. Veeva reports that eight of the top 20 biopharma companies have standardized on Vault EDC as part of their clinical data management strategy.

4. Castor EDC

Castor EDC provides a cloud-native EDC and CDMS platform that supports clinical data capture, query management, audit trails, and source data verification in a single environment. The platform uses a low-code eCRF builder that allows study teams to deploy without specialized programming expertise, and Castor publishes build times for low-complexity studies of 3--4 weeks. The platform is validated for FDA 21 CFR Part 11, ISO 27001 certified, GDPR compliant, and aligned with ICH E6(R3) and EU Annex 11 standards. Castor also supports ePRO/eCOA and eConsent natively within the same platform, enabling unified data management without middleware.

5. Medrio

Medrio offers Medrio CDMS/EDC, a no-code, point-and-click platform for clinical data collection and management across Phase I--IV commercial, MedTech, and CRO studies. The platform supports study builds and mid-study amendments without vendor programming dependency, with CDMS capabilities including data validation, query management, and audit trail management. Medrio CDMS/EDC is validated for FDA 21 CFR Part 11, compliant with HIPAA, GDPR, and ICH E6(R2), and includes role-based access controls and secure data encryption. Medrio also offers an integrated eClinical suite including ePRO/eCOA, eConsent, and RTSM as modular additions.

6. Oracle Clinical One Data Collection

Oracle offers Clinical One Data Collection, a cloud-based EDC and data collection platform that unifies clinical data from any source -- including electronic health records (EHRs), eCRFs, labs, and wearables -- into a single environment. The platform supports real-time mid-study changes without downtime and includes AI-enabled interoperability with EHR systems via Oracle Clinical Connector, enabling direct data transfer to reduce manual entry. Clinical One Data Collection integrates with Oracle's RTSM and safety solutions, and is deployed on Oracle Cloud Infrastructure for global studies across Phase I--IV and post-market contexts.

What to look for in EDC solutions for US clinical trials

FDA 21 CFR Part 11 compliance depth

In the US market, 21 CFR Part 11 compliance is the regulatory floor, not a differentiator. But the depth and accessibility of that compliance documentation matters considerably when your QA team is preparing for an FDA inspection or processing a computer system validation package. Look for platforms that provide structured compliance documentation -- not just a certificate -- including validation lifecycle documentation, audit trail specifications, and pre-built change control workflows. Viedoc's VIRP delivers exactly this: a structured, ready-to-use package that reduces your internal validation burden. Confirm whether the platform has a documented track record of FDA inspection support, not just a stated compliance posture.

HIPAA attestation for US PHI handling

Any study collecting protected health information from US subjects requires a platform with HIPAA attestation -- and HIPAA compliance requires more than data encryption. Evaluate whether the vendor has a Business Associate Agreement (BAA) process, documented access controls at the user and role level, and a defined breach notification procedure. Platforms that carry ISO 27001 and SOC 2 Type II certifications alongside HIPAA attestation provide an additional layer of auditable assurance for IT and legal stakeholders. Skipping this verification at the shortlist stage is one of the fastest routes to a late-stage deal delay when IT and legal enter the review.

No-code configurability and amendment velocity

In a US Phase I/II context, protocol amendments happen -- often more than once. The question isn't whether your platform supports amendments; it's how quickly your team can implement them independently. Platforms that require vendor-side programmers for every eCRF change introduce scheduling dependencies that compound across a concurrent study portfolio. Best-in-class platforms allow certified data managers to build, test, and deploy amendments in days, not weeks, with no system downtime. Viedoc's no-code Designer supports this model directly; the platform's amendment cycle runs in days for minor-to-mid-complexity changes, with no programmer required at any stage.

Pricing model transparency and per-seat exposure

US SMID CROs and growth-stage sponsors frequently underestimate the total cost of ownership of per-seat licensing models. A platform priced at a competitive per-study rate can become disproportionately expensive as you add users, CRAs, site staff, and monitors across a growing study portfolio. Evaluate whether the pricing model is truly per-study or carries hidden per-user, per-site, or per-amendment fees that erode margin at scale. A study-based licensing model with unlimited user seats, like Viedoc's, protects CRO margin more reliably than a model that penalizes headcount growth.

Support coverage across US time zones

For US-based trials, 24/7 support with real escalation paths matters most at three moments: database lock, site activation, and mid-study change deployment. A vendor that provides only a ticketing system -- without named account contacts or direct escalation -- creates unacceptable risk at exactly these moments. Ask vendors to describe their escalation pathway in the event of a P1 site issue at 2 AM Eastern time on a Friday. The answer tells you more about operational fit than any feature demo.

How to choose the right EDC solution for US clinical trials

Step 1: Define your compliance non-negotiables

Before evaluating features, document the specific regulatory requirements your studies must meet: 21 CFR Part 11 for electronic records and signatures, HIPAA for US PHI, and whether your studies involve FDA IND submissions that carry additional audit trail requirements. Different platforms carry different depths of compliance documentation, and the gap between "21 CFR Part 11 compliant" as a marketing claim and a platform that has passed a live FDA inspection is material. Qualification should start here, not at the demo stage.

Step 2: Assess your team's self-service capability

The economics of EDC for US SMID CROs and sponsor teams depend heavily on how much work your data management team can do independently. A platform that requires vendor-side programmers for every build or amendment adds cost and scheduling risk that compounds across a portfolio. Evaluate platforms on whether certified data managers -- not programmers -- can own the full build and amendment lifecycle, and whether the vendor offers a certified training pathway your team can complete in-house.

Step 3: Evaluate amendment velocity under realistic conditions

Most EDC demos show the best-case scenario. Ask vendors for the actual median time from change approval to deployment in a live study, for amendments of typical complexity for your protocol types. Ask specifically whether the platform requires system downtime during amendments, and what the rollback process looks like if an amendment causes data integrity issues. For Phase I/II trials with frequent protocol evolution, this is a more important evaluation criterion than headline build speed.

Step 4: Scrutinize the total cost model at study portfolio scale

A vendor's per-study price at one study looks very different from its total cost of ownership at ten concurrent studies. Walk through a realistic scenario with each vendor: your current study volume, typical concurrent user count, amendment frequency, and whether study templates and prior eCRF design can be reused. Identify every variable that changes the price and decide whether the cost model is predictable enough to quote to sponsors with confidence.

Step 5: Choose a platform built for the US SMID market

US SMID CROs and growth-stage biotech sponsors need a platform that matches their operational profile -- fast builds, transparent pricing, lean-team self-service, and FDA compliance documentation depth -- without the enterprise overhead that large pharma platforms carry. Viedoc's EDC software is built precisely for this segment: study builds in as little as 8 weeks, unlimited user seats, VIRP for FDA inspection readiness, and 24/7 customer success across 7,500+ completed studies. Book a demo or request a proposal to walk through build speed, compliance credentials, and cost in the context of your own study portfolio.

Frequently asked questions

What is the best EDC platform for US clinical trials?

Viedoc's EDC software is the strongest choice for US clinical teams prioritizing build speed, FDA compliance depth, and cost transparency. It delivers study builds in as little as 8 weeks, carries full 21 CFR Part 11 and HIPAA attestation, provides the VIRP for FDA inspection readiness, and operates on a transparent study-based pricing model with unlimited user seats. Medidata Rave EDC remains the benchmark for large pharma and complex Phase III trials with extensive FDA submission history. Castor EDC is a strong alternative for teams prioritizing native ePRO/eCOA integration with a no-code build environment.

What does FDA 21 CFR Part 11 compliance mean for an EDC platform?

FDA 21 CFR Part 11 establishes the requirements for electronic records and electronic signatures used in FDA-regulated clinical trials. For an EDC platform, this means the system must maintain a complete, tamper-evident electronic audit trail of all data entries and changes, enforce role-based access controls, support electronic signature workflows with authentication, and provide the documentation necessary to pass a computer system validation review. Compliance with 21 CFR Part 11 is a mandatory requirement for any EDC used in IND-enabled studies in the US, and your QA team will verify it during the CSV process.

How long does it take to build and deploy an EDC study?

Build timelines vary significantly by platform and study complexity. Modern no-code platforms can go live in 8--12 weeks for professionally built studies of moderate complexity. Simpler studies on platforms with strong self-service capability can go live faster. Legacy enterprise platforms with programmer-dependent configuration typically run 60--90 days from kick-off to go-live. Mid-study amendments on modern platforms typically run days for minor updates and one to two weeks for more complex changes. Understanding amendment velocity is as important as headline build speed, particularly in early-phase studies with evolving protocols.

What is the difference between 21 CFR Part 11 and HIPAA for EDC platforms?

These are separate regulatory requirements that apply in different contexts. 21 CFR Part 11 governs electronic records and signatures in FDA-regulated clinical research -- it applies to the data collection and audit trail functions of your EDC. HIPAA governs the handling of protected health information (PHI) from US subjects -- it applies when your study captures identifiable patient data. Many US clinical trials require both: 21 CFR Part 11 compliance for the EDC workflow and HIPAA attestation for the data. Confirm both independently with any platform you shortlist.

What is a Viedoc Inspection Readiness Packet (VIRP)?

The Viedoc Inspection Readiness Packet (VIRP) is a structured documentation package available to all Viedoc customers that supports computer system validation and FDA inspection preparation. Rather than requiring your QA team to build validation documentation from scratch, VIRP provides a pre-assembled, auditable record of platform compliance evidence including system validation documentation, audit trail specifications, and change control records. For US sponsors and CROs navigating FDA audits, this substantially reduces the internal preparation burden and provides a consistent, inspection-ready compliance posture across every study on the platform.

How does Viedoc's pricing model compare to per-seat EDC models?

Viedoc operates on a transparent, study-based licensing model with unlimited user seats and no per-user fees. Per-seat models can appear cost-competitive at low user counts but become disproportionately expensive as CRAs, site staff, monitors, and sponsor users are added across a growing study portfolio. For a SMID CRO managing 10--20 concurrent studies, the difference between a per-seat model and an unlimited-seat model can represent a material difference in delivery margin. Viedoc's model removes that exposure entirely.

Making the right EDC choice for US clinical trials

The US EDC market in 2026 is bifurcated between enterprise platforms designed for large pharma -- with corresponding complexity and cost -- and a growing tier of cloud-native alternatives built for SMID CROs, growth-stage sponsors, and lean clinical teams. Each platform reviewed here takes a different approach to the same core problem: how to collect, validate, and deliver high-quality clinical data within the timelines and cost structures that matter to your organization.

US buyers consistently weight two variables above all others: speed to first patient in and predictable total cost of ownership across a study portfolio. EMEA and APAC buyers weight compliance credentials and vendor stability more heavily; US clinical teams, while equally serious about FDA compliance, tend to make the first call on build velocity and pricing model clarity. The global eClinical software market is estimated at over $11 billion in 2025 and growing at approximately 14% annually -- which means new entrants and acquisitions will continue to reshape the shortlist. Evaluate platforms against your actual requirements, not their market positioning.

Platform switching in regulated clinical research is not trivial. Every change requires revalidation, SOP updates, and retraining of site and data management staff. The cost of switching compounds with every additional study on the incumbent platform. Choosing the right platform at the outset -- one that can grow with your study portfolio and comply with evolving FDA requirements -- is a significantly more defensible decision than optimizing for the lowest per-study cost in the first year.

Why Viedoc is the best EDC choice for US clinical trials

If you're running Phase I/II studies and need a platform that your data management team can configure, amend, and manage independently -- without waiting on a vendor's programming queue -- Viedoc is built for that operational model. Study builds go live in as little as 8 weeks. Amendments run in days. The no-code Designer allows certified data managers to own the full build lifecycle, and the Viedoc CRO partner program provides tiered partnership benefits for CROs standardizing at portfolio level.

Viedoc is FDA 21 CFR Part 11 compliant, carries HIPAA attestation for US PHI handling, and is ISO 27001 and SOC 2 Type II certified -- the credentials your IT and QA teams will require during evaluation. The VIRP gives your team a ready-to-deploy computer system validation package that removes preparation burden ahead of FDA inspections. The platform runs at 99.99% uptime on Microsoft Azure, with 24/7 customer success available via direct escalation -- not a ticket queue.

With 7,500+ completed studies across 30,000+ sites in 75+ countries, founded in 2003 and continuously deployed in regulated commercial trials for 20+ years, Viedoc carries the track record that builds committee confidence. The modular suite -- covering EDC, ePRO, RTSM, eTMF, Televisit, eSignature, and medical coding -- means you can expand without changing platforms as your study portfolio matures.

If you're evaluating EDC options for your next study or a broader portfolio standardization, book a demo or request a proposal and we'll walk you through build speed, compliance credentials, and cost against your own study profile.